– Veterinary Pharmaceutical Solutions (VPS), a leader in livestock pharmaceutical compounding, is proud to announce its strategic expansion into poultry including chickens and turkeys. This is marked by two major milestones: the appointment of a commercial director of poultry and the presentation of groundbreaking research at the American Association of Avian Pathologists (AAAP) annual conference.
VPS recently welcomed Darrell Stoner as Commercial Director-Poultry. Stoner brings over 20 years of experience from Elanco’s poultry division and currently serves as Chair of the Health & Welfare Committee for the International Poultry Welfare Alliance (IPWA). He also sits on the boards of The Poultry Federation and the National Turkey Federation. In his new role, Stoner will deepen engagement with poultry integrators and veterinarians to develop innovative solutions in the poultry industry.
In addition, Dr. Brian Payne, VPS Commercial R&D and Technical Service Director, was selected to present at the American Association of Avian Pathologists (AAAP) conference held in Portland, July 29–31. His presentation focused on VPS’s Meloxicam residue study in finishing-age turkeys, conducted in collaboration with Iowa State University. The study supports informed withdrawal time recommendations for Meloxicam and ibuprofen, currently the only legally available water-soluble NSAIDs for use in poultry and livestock.
Dr. Payne, an experienced technical veterinarian with two decades of industry experience, has long served the veterinary community through research and technical support. His selection to present at AAAP underscores VPS’s commitment to advancing animal health through science and innovation.
“VPS is well-known among swine veterinarians and producers for its high-quality compounded medications,” said Stacy Peters, Chief Commercial Officer. “We’re excited to strengthen relationships with poultry veterinarians and integrators by continuing to deliver customized solutions that protect and improve flock health.”
